– USA, NJ – Bone Biologics, Corp., a company developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or Nell-1) today announced the appointment of George Oram to the Board of Directors.
Mr. Oram has over 30 years of large and small healthcare and biotechnology company experience. Over his career Mr. Oram has served as President or senior executive of a number of medical device and pharmaceutical development companies including positions as President of Orthologic Corporation, a $70 million medical device company, and Executive Vice President of the Musculoskeletal Transplant Foundation.
“We are pleased to welcome George to our Board of Directors,” said Bruce Stroever, Bone Biologics Chairman. “His many years of experience across medical device and healthcare, as well as his deep background in product development and strategic planning will be a valuable addition to the Company.”
About Bone Biologics
Bone Biologics was founded by University of California Los Angeles professors in collaboration with an Osaka University professor, and a USC surgeon in 2004. Formed to pursue regenerative medicine for bone, the company currently has as its strategic partners the Musculoskeletal Transplant Foundation, the nation’s leading tissue bank and Orthofix, a leading global medical device company. Bone Biologics is currently focused on bone regeneration in spinal fusion using its recombinant human protein known as Nell-1. Nell-1 is an osteoinductive orthobiologic; a recombinant protein that regulates and accelerates bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.